New options for investors seeking all-in-one alternatives exposure.
The year 2012 was a big one for multialternative mutual funds. The category saw 17 new offerings last year, the second-highest number of launches in the alternatives space. Although the rate of inflows hasn't accelerated as quickly as the product launches, flows have been strong--more than $4 billion, each year, for the past two years. And assets in the category reached $17.9 billion last year, representing an increase of 37.2% from 2011. Even more surprising, however, is the amount of assets raised in the newly launched funds. Six of the 17 new funds have $100 million in assets, and one raised more than $700 million. By comparison, the long/short equity category saw 15 new offerings last year, but only two have raised more than $100 million.
It's clear that many investors are becoming more interested in alternatives exposure, and these multialternative funds are intended to serve as a one-stop-shop solution, saving investors the hassle of deciding which alternative strategies and managers to allocate to, and how much. But before investors dive in, it's important to know that there are various flavors of multialternative funds, and some may suit one's needs better than others.
Replication or the Real Deal?
Some of the first multialternative mutual funds were hedge fund replicators. At the heart of the idea was that hedge funds, on average, don't generate alpha but instead offer investors a favorable mix of beta (market) exposures (such as emerging markets or credit). If that were true, the thinking was that a prudent investor could allocate to a hedge fund replicator, which invests in those "betas" via exchange traded-funds or futures contracts, without the "2 and 20" fee structure (where investors pay a 2% management fee and give up 20% of any gains to the firm running the hedge fund) and onerous liquidity terms. In practice, however, replicators haven't performed as expected. Goldman Sachs Absolute Return Tracker GARTX and Natixis ASG Global Alternatives GAFAX, for example, receive Morningstar Ratings of 2 stars, reflecting their subpar risk-adjusted performance.
As mutual funds of actual hedge fund managers are encroaching into the multialternative space, the idea of hedge fund replication is losing its luster. These two funds lost $386.8 and $283.8 million, respectively, in 2012, more than any other funds in the category. Conversely, Bronze-rated IQ Alpha Hedge Strategy IQHIX, a more actively managed replication strategy, managed to entice a few investors. This fund bested its replication peers in 2012, gaining 4.75%.
The funds doing the most active, hedge-fund-like strategies themselves, such as JHancock2 Global Absolute Return Strategies JHAAX, Arden Alternative Strategies ARDNX, and AQR Multi-Strategy Alternative ASAIX, received the bulk of the multialternatives category's inflows ($1.5 billion, $729.1 million, and $524 million, respectively) in 2012. The John Hancock and AQR offerings are internally managed multistrategy funds, while the Arden fund is a fund of external hedge fund managers. Both strategies can fulfill a need.
Build or Buy?
When selecting an actively managed multialternative fund, investors must understand if the offering is a combination of internally managed strategies or a combination of external subadvisors. There are pros and cons to each model.
Internally managed multistrategy funds, for example, have the ability to control risk and all positions in-house--netting out overlapping positions between strategies, for example--all at a reasonable cost compared with its peers. The downside is that they may combine strategies that aren't core to the fund shop's expertise. In addition, some internally managed funds are not diversified enough to serve as a "one-stop-shop" alternatives solution.
AQR Multi-Strategy Alternative overcomes both of these obstacles. For 1.99% (on the Institutional shares), management offers a wide range of in-house strategies, including arbitrage, managed futures, and long-short equity, which it has been managing successfully in private products since the 1990s. The fund's correlation to the S&P 500 and the Barclays U.S. Aggregate Bond Index is low, 0.23 and negative 0.04, respectively (using weekly data since inception through January 2013). Theoretically, low correlations, coupled with positive performance, can increase investor risk-adjusted returns. Its performance (0.02 since inception through Feb. 4, 2013) could be better, though.